AI Data Quality in Clinical Trials: A Practical Guide

Data manager reviewing clinical trial records

AI improves clinical trial data quality when it does a few specific jobs well: it spots discrepancies across data sources, ranks queries by risk, groups similar issues and suggests standardized coding. People then review and approve what it finds. It does not replace data management. It gives your team more time for judgment calls, provided you can show regulators what the tool did, which version did it and who signed off.

This guide is for sponsors, CROs, clinical operations leads and study directors. It covers where AI fits in the trial data lifecycle, what it has demonstrated so far, what can go wrong and how to evaluate a tool before you rely on it. It also covers a point that is easy to overlook: no model can fix a specimen that was collected, handled or labeled badly.

Kohealth Labs

Build Better Data from the Start

KoHealth Labs supports clinical studies with specimen collection and management, laboratory testing, biomarker analysis, and flexible diagnostic solutions.

Explore KoHealth Labs

TL;DR

AI is most useful for smart data queries, cross-source discrepancy checks, risk-ranked query lists, medical coding suggestions and classifying free-text protocol deviations.
Published examples show real gains, such as a 50% shorter time from data entry to query generation, but results depend on the data the model sees.
FDA’s January 2026 principles call for risk-based validation tied to a defined context of use, and ICH E6(R3) expects documented responsibilities and audit trails for computerized systems.
Humans stay accountable. Every AI output should trace to a model version, its source data and a named reviewer.
Upstream quality still decides the outcome: specimen collection, assay validation and lab data delivery set the ceiling for any AI layer.

What AI-enabled data quality means in a trial

Data quality in a clinical trial means the dataset is accurate, complete, consistent and traceable back to its source. AI-enabled data quality means using machine learning, and increasingly large language models, to help check those properties at a scale and speed that manual review and fixed edit checks cannot match.

A review in the Journal of the Society for Clinical Data Management lists the use cases being explored: smart data queries, wearable-data attribution, protocol-deviation trending, external control arms, complaint handling, patient stratification and patient enrichment. Not all of these are about cleaning data. Some use AI to decide which data to trust, which patients to enroll or how to read deviations.

The concept is also tied to the data itself. The authors of an NIH-hosted review of AI and innovation in trials note that the accuracy and performance of AI models depend on the quality and completeness of the data they are given. Put plainly, AI is both a way to improve data quality and a system that needs good data to work.

Where AI fits across the data lifecycle

It helps to think in three stages: design, conduct and close-out. The questions differ at each.

Before the first patient: design and collection

Quality starts with deciding what to collect. The Clinical Trials Transformation Initiative (CTTI) recommends collecting the minimum data set needed for the endpoints, defining appropriate metadata and sampling, and making sure digitally captured data are accurate, complete and correctly attributable. That is a human design decision, and no AI tool compensates for collecting the wrong things.

AI can then help with setup. Some CRO platforms generate draft SDTM mappings from protocol content and EDC metadata, then update them as the protocol is amended, so standardized data and quality checks are ready earlier. The value is speed and consistency, as long as a data manager reviews the mappings.

During conduct: the daily work of cleaning

This is where most teams first see value. Conventional data management relies on predefined edit checks and manual review. AI adds contextual pattern detection and risk prioritization across data sources, while human experts keep final review, interpretation and accountability.

In practice, that means your data managers open a queue that has already been sorted by likely impact instead of working through every flag in the order it fired.

At close-out: consistency and lock

Before database lock, AI can scan for residual inconsistencies across datasets, check coding and support trending of deviations. The benefit here is fewer late surprises. The risk is trusting a late-stage model that nobody has validated for the study at hand.

Which data problems AI can detect

The strongest evidence is for tasks with a clear pattern and a clear human check afterward.

Problem	What AI does	Human step
Cross-source discrepancies	Flags mismatches across adverse-event, concomitant-medication and medical-history data	Reviewer confirms or dismisses each flag
Query overload	Groups similar issues and ranks queries by risk	Data manager decides which to send
Medical coding	Recommends standardized terms	Coder approves or corrects
Open-text protocol deviations	Classifies entries into predefined categories	Clinical team verifies categories and trends
Imaging endpoints	Assesses features such as tumor displacement	Radiology reviewer makes the endpoint call

The first rows draw on CTTI’s AI workgroup summary, which describes machine learning flagging records across adverse-event, concomitant-medication and medical-history datasets for human review, and AI tools assessing tumor displacement from imaging. The review in JSCDM adds that large language models can classify open-text protocol deviations into predefined categories, which can reduce manual classification effort and may improve accuracy and granularity. A separate industry source describes AI that identifies likely discrepancies, groups similar issues, ranks queries by risk and recommends standardized coding for human review.

Notice the pattern in the last column. AI proposes, a qualified person disposes.

What the evidence shows on speed and accuracy

The numbers are encouraging but narrow. In one smart data query case, time from data entry to query generation fell by 50%, with 85% to 90% accuracy. That accuracy figure matters as much as the speed gain: at 85% to 90%, one query in every ten or so is wrong, which is why a review step is non-negotiable.

Broader estimates are larger. A comprehensive review of AI in clinical trials, searching literature through December 2024, reports that AI integration accelerates trial timelines by 30% to 50% and reduces costs by up to 40%. Treat that as a range reported across the literature rather than a promise for your study. Your results will depend on the data, the indication, the tool and how well your team uses it.

A scoping review posted in 2026 adds a useful caution: AI tools are already used in production, yet the evidence validating them is of low quality, and the authors call for more rigorous comparative validation studies. If a vendor shows only a case study, ask for your own pilot.

Risks you need to manage

The FDA has been direct about the limits. Its officials describe risks that include bias from training data, difficulty understanding model conclusions and performance degradation over time. They also note that variability in the quality, size and representativeness of training data can introduce bias and raise questions about reliability.

Translate that into trial operations:

False alerts. A model that over-flags burns reviewer time. One that under-flags lets errors through. Track both rates during a pilot.
Bias. If a model learned from one population or one kind of site, it may behave differently at yours.
Explainability. Transparency helps users decide, though explainability may not be strictly required, and human-in-the-loop systems can mitigate black-box limitations.
Drift. Performance changes over time. FDA principles call for scheduled monitoring and periodic re-evaluation of AI technologies, including to address data drift.
Rubber-stamping. A 2026 academic review argues that human review should be an accountable decision point, not a superficial confirmation.

What FDA and ICH E6(R3) expect

Two documents frame the US conversation.

First, FDA’s January 2026 Guiding Principles of Good AI Practice in Drug Development say AI technologies should follow a risk-based approach, with validation, risk mitigation and oversight proportionate to the context of use and model risk. The same document calls for a clear context of use, risk-based performance assessment and quality management across the technology’s life cycle.

Second, ICH adopted E6(R3) Principles and Annex 1 on January 6, 2025, and it calls for risk-based validation, change control and documented responsibilities for computerized systems. It also expects sponsor responsibilities and those of other parties to be clear and documented when activities are transferred. That matters when a CRO or vendor runs an AI tool on your behalf. An academic review of AI-aided clinical data management reads E6(R3) as requiring risk-proportionate validation and audit-trail maintenance for computerized systems, alongside traceable documentation of data provenance, processing steps and human-AI interactions.

Accountability questions are practical. One industry brief on AI-generated queries argues that sponsors should be able to identify the model version and responsible operator for any AI output. For electronic records within 21 CFR Part 11’s scope, the same source notes that applicable predicate rules and a documented risk assessment determine the appropriate controls. For a deeper look at what counts as a regulated record in lab data, see our guides on 21 CFR Part 11 compliance and Part 11 lab data.

What FDA and ICH E6(R3) expect — overview diagram

How to evaluate an AI data quality tool

Use this sequence before a tool touches live study data.

Define the context of use. Write one sentence: what the tool does, on which data, and what decision it informs. FDA’s principles start here.
Check the training and input data. AI training data should be fit for purpose and reliable, including accuracy, completeness and traceability.
Pilot against your own data. Measure precision and recall of flags against what a trained reviewer finds. Do not accept vendor averages.
Set acceptance criteria and reviewer qualifications in an SOP. Guidance on AI SOPs recommends minimum reviewer qualifications and clear criteria for accepting or rejecting AI-generated content.
Build traceability in. Outputs should link to source data, model version and configuration, and your records should show recommendations, user decisions, overrides and final actions, as described here.
Monitor on a schedule. Re-check performance when protocols are amended, sites are added or the vendor updates the model.

The same discipline applies in clinics. If your practice also uses AI to review documentation, an AI documentation audit pilot shows how scoring, alerts and physician sign-off can be structured so every AI-drafted correction has a named human behind it.

AI cannot fix what happens before the data exists

Most data quality conversations start in the database. Many errors start earlier, at the bedside, in the tube or in the transport box. A mislabeled specimen, a delayed spin or a wrong collection tube produces a result that looks like data and behaves like noise. An AI tool may flag the outlier, but it cannot tell you whether the sample was compromised.

Specimen handling errors affect trial data

That is why central lab operations belong in any data quality plan. Our article on preanalytical variables and AI-based quality checks covers how collection and handling errors arise and how to catch them. Assays need to be fit for purpose before the first sample is run, which we cover in our practical guide to assay validation in clinical trials. And timing matters: faster data delivery improves clinical trial outcomes because queries can be raised while the site still remembers the visit.

Our perspective

We run a laboratory, so we see data quality from the specimen side. Our view is that AI works best when three conditions hold.

First, the source data are clean at the point of collection. Standardized collection kits, courier pickup, clear labeling and consistent processing remove a large share of the noise that downstream models would otherwise have to untangle.

Second, results arrive in a form the study team can use without rework. That means analysis-ready data, EMR and LIS integration and delivery aligned to the regulatory expectations of the study, rather than files that someone has to reformat before any quality check can run.

Third, a person stays responsible. We would rather give a data manager a well-sorted list and a full audit trail than a black box with a confidence score. Sponsors and CROs are right to ask who reviewed an output, with which model version, and why they accepted it.

The science is moving quickly, and we find that encouraging: tools that once took weeks of manual reconciliation now surface problems in hours. The teams that benefit most are the ones that treat validation, documentation and human oversight as part of the tool, not as paperwork around it.

— Kohealth Labs

Bringing lab and imaging data into your quality plan

If you are a CRO, sponsor or research site building an AI-assisted quality process, the lab is a natural place to start. KoHealth Labs provides specimen collection and management, courier pickup, biomarker analysis, electronic results reporting and analysis-ready data delivery for clinical research. You can see how this fits together on our clinical trials laboratory services page, review the data and AI approach, or schedule a specimen pickup to start a conversation about your study.

FAQ

Can AI replace clinical data managers?

No. AI can sort, flag and suggest, but qualified professionals remain responsible for interpretation, approval and accountability. The role shifts toward reviewing, validating and managing exceptions rather than checking every record.

Does the FDA allow AI in clinical trial data management?

The FDA’s January 2026 principles describe a risk-based approach in which validation and oversight are proportionate to the AI’s context of use and model risk. They do not ban AI. They expect you to define what the tool does, document how it was assessed and monitor it over time.

What is the biggest risk of AI in trial data quality?

Over-trust. Training-data bias, hard-to-explain conclusions and drift over time are all documented concerns, and a reviewer who confirms flags without real scrutiny removes the safeguard. Pilot the tool on your own data and keep review decisions documented.

Does better lab data really improve AI results?

Yes. AI models depend on the quality and completeness of the data they receive, so clean collection, validated assays and timely, structured delivery from the lab give any downstream tool a stronger starting point.

Sources

For more information about our diagnostic testing, clinical research laboratory services, or partnership opportunities, visit https://kohealthlabs.com or contact KoHealth Labs at (469) 792-8439 and ask for Amy Patterson.